FDA Grants Accelerated Approval to Emrelis for NSCLC With High C-Met Protein Overexpression

The FDA granted accelerated approval to telisotuzumab vedotin-tllv (Emrelis, AbbVie), a c-Met−directed ...

MAY 20, 2025